Encyclopedia of Cancer

Living Edition
| Editors: Manfred Schwab

Non-Small-Cell Lung Cancer

  • Rafael Rosell
  • Delvys Rodriguez-Abreu
Living reference work entry
DOI: https://doi.org/10.1007/978-3-642-27841-9_4119-3


Advanced non-small-cell lung cancer (NSCLC) is a dismal disease, though outcomes can be improved when cisplatin treatment is customized on the basis of gene expression profiling. In addition, patients with epidermal growth factor receptor (EGFR) mutations attain a 70 % response and prolonged survival to targeted therapies, but drug resistance can be mediated by expression of DNA repair genes, including expression of the breast cancer susceptibility gene 1 (BRCA1).

Two treatment approaches for advanced NSCLC patients can be carried out in large clinical trials of treatment customized by molecular analyses:
  • For patients without EGFR mutations, personalized chemotherapy based on the BRCA1-receptor associated protein 80 (RAP80)

  • For patients with EGFR mutations, EGFR tyrosine kinase inhibitors (TKIs) plus EGFR T790M inhibitors or individualized chemotherapy based on BRCA1 mRNA levels


Survival Rates

The median survival of patients with advanced or metastatic NSCLC...


Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Mutation Epidermal Growth Factor Receptor Gene T790M Mutation BRCA1 Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in to check access.


  1. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, Harkin DP (2003) Cancer Res 63:6221–6228PubMedGoogle Scholar
  2. Rosell R, Skrzypski M, Jassem E, Taron M, Bartolucci R, Sanchez JJ, Mendez P, Chaib I, Perez-Roca L, Szymanowska A, Rzyman W, Puma F, Kobierska-Gulida G, Farabi R, Jassem J (2007) PLoS ONE 2:e1129CrossRefPubMedPubMedCentralGoogle Scholar
  3. Rosell R, Perez-Roca L, Sanchez JJ, Cobo M, Moran T, Chaib I, Provencio M, Domine M, Sala MA, Jimenez U, Diz P, Barneto I, Macias JA, de Las Penas R, Catot S, Isla D, Sanchez JM, Ibeas R, Lopez-Vivanco G, Oramas J, Mendez P, Reguart N, Blanco R, Taron M (2009a) PLoS ONE 4:e5133CrossRefPubMedPubMedCentralGoogle Scholar
  4. Rosell R, Viteri S, Molina MA, Benlloch S, Taron M (2009b) Curr Opin Oncol 22:112–120CrossRefGoogle Scholar
  5. Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sanchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M (2009c) N Engl J Med 361:958–967CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Catalan Institute of OncologyHospital Germans Trias i PujolBarcelonaSpain
  2. 2.Hospital Universitario InsularLas Palmas de Gran CanariaSpain